Right! And, iirc, we might expect some sort of update in January??? If nothing else it would be on patient enrollment, which imo would be nice to know.
I just haven't had the time to keep up, or go back and check.
Also, three things on my post you responded to: 1) Note, just to be clear, MRKR leases the manufacturing facility - they didn't buy and build. I meant they set it up and got it operational.
2) I forgot to mention the major insider buys last spring- I'm sure they're disappointed in the current share price, but likely too busy to notice or dwell on it.
3) I also forgot the $13mil Grant from the Cancer Research Institute of Texas that they got a couple months ago. That's a decent chunk of change and they don't give that kind of money out w/o some major DD before hand.
I'm a glass-half full kinda guy too, and I'm frustrated with the opportunity cost, but the delay I think was mostly beyond their control. That FDA hold - over a cell culture reagent that isn't administered to the patient - and which was used in all the other studies . . . man that still seems screwy to me. I understand the reagent was from a new source but unless it's plutonium or something I don't get that.
But yeah, it's almost next year, and with two more centers joining, that's two more points of entry for study participants.
Hopefully we'll have good news on enrollment sometime in the next few months.
News 
Market Data 
Discover 
